[go: up one dir, main page]

NO961797D0 - Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter - Google Patents

Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter

Info

Publication number
NO961797D0
NO961797D0 NO961797A NO961797A NO961797D0 NO 961797 D0 NO961797 D0 NO 961797D0 NO 961797 A NO961797 A NO 961797A NO 961797 A NO961797 A NO 961797A NO 961797 D0 NO961797 D0 NO 961797D0
Authority
NO
Norway
Prior art keywords
hco3
yields
independent
preparation
treatment
Prior art date
Application number
NO961797A
Other languages
English (en)
Other versions
NO961797L (no
Inventor
Ludovic Durand
Jean-Paul Babingui
Claudie Moulin
Sylvie Robert-Piessard
Guillaume Le Baut
Elisabeth Scalbert
Daniel-Henri Caignard
Pierre Renard
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of NO961797D0 publication Critical patent/NO961797D0/no
Publication of NO961797L publication Critical patent/NO961797L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
NO961797A 1995-05-05 1996-05-03 Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter NO961797L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9505361A FR2733685B1 (fr) 1995-05-05 1995-05-05 Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant

Publications (2)

Publication Number Publication Date
NO961797D0 true NO961797D0 (no) 1996-05-03
NO961797L NO961797L (no) 1996-11-06

Family

ID=9478712

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961797A NO961797L (no) 1995-05-05 1996-05-03 Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter

Country Status (9)

Country Link
US (1) US5703118A (no)
EP (1) EP0740936A3 (no)
JP (1) JPH08301754A (no)
CN (1) CN1136920A (no)
AU (1) AU5204396A (no)
CA (1) CA2175747A1 (no)
FR (1) FR2733685B1 (no)
NO (1) NO961797L (no)
ZA (1) ZA963520B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008208A (en) * 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPILATIONS AND METHOD FOR TREATING BONE DEFICIENCY
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1206442A4 (en) * 1999-08-24 2004-12-29 Univ Virginia Commonwealth CHIRAL ALLOSTERIC MODIFIERS OF HEMOGLOBIN
FI20011507A0 (fi) * 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
PL372695A1 (en) 2002-06-19 2005-07-25 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
FI20030030A0 (fi) * 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
US20070259966A1 (en) * 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
US8349066B2 (en) * 2006-09-21 2013-01-08 Ppg Industries Ohio, Inc. Low temperature, moisture curable coating compositions and related methods
CN101274765B (zh) * 2007-03-30 2011-11-30 中国石油化工股份有限公司 一种含贵金属的微孔钛硅材料及其制备方法
CN104250253B (zh) * 2014-09-12 2017-04-05 辽宁大学 取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
JPH02215778A (ja) * 1989-02-14 1990-08-28 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びその医薬用途
US5099012A (en) * 1990-12-11 1992-03-24 Eastman Kodak Company Chroman-2-carboxamide conjugates and their use for treatment of reperfusion injury
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
FR2733685B1 (fr) 1997-05-30
EP0740936A2 (fr) 1996-11-06
CA2175747A1 (fr) 1996-11-06
EP0740936A3 (fr) 1997-01-15
CN1136920A (zh) 1996-12-04
FR2733685A1 (fr) 1996-11-08
NO961797L (no) 1996-11-06
US5703118A (en) 1997-12-30
AU5204396A (en) 1996-11-14
ZA963520B (en) 1996-11-13
JPH08301754A (ja) 1996-11-19

Similar Documents

Publication Publication Date Title
NO914667L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylderivater
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
BR9607791A (pt) Formulação oral de 2-metil-tieno-benzodiazepina
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
FI955310L (fi) Farmaseuttinen koostumus flavonoidien antamiseksi oraalisesti
NO953367D0 (no) Anvendelse av substituerte 4-fenyl-6-amino-nikotinsyre-derivater som legemidler
ZA983602B (en) Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination
NO961797D0 (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
NO982237L (no) FremgangsmÕte for fremstilling av fenylimidazolidinderivater
FI971527L (fi) Indolijohdannaisten käyttö erilaisten sairauksien hoitoon
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
NO914053L (no) Fremgangsmaate for fremstilling av 8-klorokinolonderivater
HUP9901247A3 (en) Use of naphthimidazole-, naphthoxazole- and naphthothiazole-diones for the preparation of pharmaceutical compositions treating diseases caused by vascular function deficiency
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
NO914985L (no) Fremgangsmaate for fremstilling av 15-nitro-tabersonin-derivater
IT1277117B1 (it) Composizioni farmaceutiche per il trattamento delle ipercolesterolemie
NO20001895D0 (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
NO914452L (no) Fremgangsmaate for fremstilling av isokinolinderivater
HUP9801985A3 (en) Use of cystine derivatives for the preparation of pharmaceutical compositions useful for the treatment of restenosis
NO943480L (no) Fremgangsmåte for direktetilpasning av proteser
NO972129D0 (no) Fremgangsmåte for fremstilling av 1-halo-3-trialkylsilanyl-benzenderivater
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
NO964519D0 (no) Fremgangsmåte for fremstilling av chitosanalkylderivater
NO994140L (no) Farmasöytisk sammensetning for den programerte frigivelse av deksfenfluramin
NO974458D0 (no) Fremstilling av cis-4-O-beskyttede-2-cyklopentenolderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application